Nexvet's Q4 loss doubles; ARTES strikes vaccine deal with Boehringer; Tyson ditches human antibiotics in chicken production;

> Newly public Nexvet ($NVET) announced that its net loss in the fourth quarter of 2014 doubled year over year to $2.4 million and that its current cash store is $21.7 million. Release

> ARTES Biotechnology and Boehringer Ingelheim Animal Health announced a collaboration to develop vaccines for veterinary use. Release

> Tyson Foods is no longer using gentamicin, an antibiotic used to treat human disease, in its chicken production. Article

> The International Federation for Animal Health has named George Heidgerken to a two-year term as president. Release

> Traverse Biosciences has formed a license agreement with the Research Foundation for the State University of New York to develop a product to treat periodontal disease in dogs. Release

> The FDA has issued a draft guidance for animal producers to better identify and prevent feed contaminants that could threaten the health of farm animals. Release

> Galileo Diagnostics has been appointed international veterinary distributor for D-Eye's Portable Retinal Imaging System. Release